Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lenalidomide in multiple myeloma.

Sheeba K Thomas1, Tiffany A Richards, Donna M Weber

  • 1The University of Texas M.D. Anderson Cancer Center, Department of Lymphoma and Myeloma, 1515 Holcombe BLVD, Box 429, Houston, TX 77030, USA.

Best Practice & Research. Clinical Haematology
|December 12, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myeloma.

British journal of haematology·2026
Same author

D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison.

Leukemia & lymphoma·2026
Same author

D-VRD induction and autologous transplant in patients ≥70 years.

Blood cancer journal·2026
Same author

Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up.

Blood advances·2026
Same author

Association of genetic ancestry with outcomes and toxicity of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.

Blood cancer journal·2026
Same author

Refining prognostic tools in Waldenström macroglobulinemia.

Blood advances·2026
Same journal

CAR-T cell therapy for multiple myeloma: An update on the current state and future potential.

Best practice & research. Clinical haematology·2025
Same journal

Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use.

Best practice & research. Clinical haematology·2025
Same journal

Immune therapy of haematological cancers.

Best practice & research. Clinical haematology·2025
Same journal

Advances in NK cell therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Adoptive cellular therapies in multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Bispecific T-cell engager therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
See all related articles

Lenalidomide offers improved efficacy and safety for multiple myeloma treatment compared to older regimens. This thalidomide analog shows significant clinical activity in newly diagnosed and relapsed patients.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Multiple myeloma treatment historically relied on melphalan-prednisone and VAD regimens.
  • These older treatments yielded limited response rates (45-55%) and complete remission rates (up to 10%).
  • Emerging therapies like thalidomide and bortezomib improved response rates but introduced side effects.

Purpose of the Study:

  • To evaluate the role of lenalidomide, a thalidomide analog, in managing multiple myeloma.
  • To assess lenalidomide's efficacy and toxicity profile compared to existing treatments.
  • To describe lenalidomide's application in various patient populations, including newly diagnosed and relapsed/refractory cases.

Main Methods:

  • Review of clinical data on lenalidomide in multiple myeloma patients.

Related Experiment Videos

  • Analysis of treatment outcomes including response rates and complete remission rates.
  • Assessment of lenalidomide's side effect profile.

    • Main Results:

    • Lenalidomide-based combinations achieve higher response rates (85-95%) and complete remission rates (up to 25%) compared to older regimens.
    • Lenalidomide demonstrates significant clinical activity in patients with multiple myeloma.
    • Lenalidomide was developed to improve upon the efficacy and toxicity of thalidomide.

    Conclusions:

    • Lenalidomide represents a significant advancement in multiple myeloma therapy.
    • It offers a more favorable efficacy and toxicity profile for patients.
    • Lenalidomide is a valuable therapeutic option for newly diagnosed, relapsed/refractory multiple myeloma, and primary amyloidosis.